Anticholinergic therapy
PreclinicalSmall molecule
Anticholinergic therapy is one of 64 small molecule programs targeting Overactive Bladder. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
58 competitors in Children
#DrugCompanyPhaseTrials
1Promacta
GSKApproved
Ozempic
Novo NordiskApproved
Gleevec
NovartisApproved
Oncaspar
SServier
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Byetta
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Somavaratan
Novo NordiskPhase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anticholinergic therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Ghent